KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.

Triin Umbleja, Mohammad U Zafar, Sara McCallum, Arijeet K Gattu, Markella V Zanni, Gerald S Bloomfield, Carlos D Malvestutto, Carl J Fichtenbaum, Judith S Currier, Craig A Sponseller, Marissa R Diggs, Sarah M Chu, Alex B Lu, Marshall J Glesby, Jack T Stapleton, Michael Frank, Kim-Lien Nguyen, Rachel A Bender Ignacio, Win Min Han, Pamela S Douglas, Judith A Aberg, Heather J Ribaudo, Steven K Grinspoon

Lancet HIV 13(5) e316-e326

PMID41936375
PMCIDPMC13122762
DOI10.1016/S2352-3018(26)00031-7
发表日期2026-04-05
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1::森林图/亚组分析图;Figure 2::森林图/亚组分析图;Figure 3::CONSORT/入组流程图。
摘要

摘要

BACKGROUND: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) found a 36% reduction in major adverse cardiovascular events (MACE) with pitavastatin in people with HIV. Little is known about the relationship between lipid lowering and MACE in this population. We evaluated pitavastatin effects on lipids and examined mediation of pitavastatin effects on MACE through lipid lowering. METHODS: REPRIEVE was a randomised, double-blind, placebo-controlled phase 3 trial evaluating pitavastatin (4 mg daily) or placebo for prevention of MACE in people with HIV. Participants aged 40-75 years, on stable combination antiretroviral therapy (ART), and at low-to-moderate atherosclerotic cardiovascular disease risk with minimally elevated LDL were followed up for a median of 5·6 years. Centrally tested fasting lipids were captured at entry and annually thereafter. The primary MACE outcome, reported previously, was time to first MACE. Here, we report secondary outcomes on fasting lipids. Linear mixed-effects models were used for assessment of the pitavastatin effect on lipids, Cox regression for relationship of lipids to MACE, and Vansteelandt method for mediation analysis. FINDINGS: REPRIEVE enrolled 7769 participants from March 26, 2015, to July 31, 2019, in 12 countries across five Global Burden of Diseases super-regions. The median baseline LDL was 108 mg/dL, and similar across treatment groups. Pitavastatin effects were primarily observed on LDL, with a modest reduction in triglycerides and no apparent effect on HDL. Based on the longitudinal data modelling, the estimated treatment group difference in LDL at month 12 (pitavastatin minus placebo) was -30 mg/dL (95% CI -31 to -29), corresponding to a 30% reduction. The estimated risk of LDL of ≥100 mg/dL at month 12 was 0·18 in the pitavastatin group and 0·57 in the placebo group (relative risk 0·32, 95% CI 0·30-0·34). A 30% lower time-updated average LDL was associated with 20% lower risk of primary MACE (hazard ratio 0·80, 95% CI 0·68-0·94). Of the pitavastatin effect on MACE, 68% was estimated to be mediated through LDL, although with low precision (95% CI 15-574). INTERPRETATION: LDL is strongly related to MACE, and LDL lowering should be an important goal of primary cardiovascular prevention in people with HIV, even in those with minimally elevated LDL. Treatment should aim to achieve accepted primary care prevention targets for LDL. FUNDING: US National Institutes of Health, Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:Pitavastatin Effect on LDL-C at Month 12 in Prespecified Baseline Subgroups, Estimated from Modeling Analyses Pitavastatin effect on LDL-C as an outcome is presented. Panel (a): Difference in absolute LDL-C level at month 12 (pitavastatin minus placebo); Panel (b): Ratio of LDL-C relative to baseline at month 12 (pitavastatin/placebo); Panel (c): Relative risk of LDL-C ≥70 mg/dL at month 12 (pitavastatin/placebo). Each factor was included as a covariate in a separate linear mixed-effects model (GEE model for the binary outcome), adjusted for natal sex and screening CD4 count. Modification of pitavastatin effect on outcomes post-entry was assessed via covariate interaction with treatment. For reference, the overall pitavastatin effects at month 12 are shown on top. The orange reference lines represent the 95% CI around the estimated overall pitavastatin effect. Given the high precision, the orange shading represents +/− 5 mg/dL (panel a) and +/− 5% (absolute, panels b and c) around the estimated overall pitavastatin effect. Smaller differences were not considered to be clinically meaningful. For numbers of participants and observations, refer to Figure S9 . *Baseline subgroups by LDL-C were defined according to screening LDL-C used to assess for eligibility.
非 KM Figure
Figure 2:LDL-C and TG Effects on MACE Outcomes LDL-C and TG were evaluated individually as time-updated covariates in Cox proportional hazards models for each of the MACE outcomes (in bold) based on all 7769 participants enrolled, unadjusted and adjusted for ASCVD risk by PCE, GBD region and race. The most recent LDL-C and TG levels prior to event, and average of the levels prior to event were evaluated; the most recent LDL-C prior to event was also evaluated by the specified clinical thresholds. For visual purposes, HR (95% CI) are plotted on the log scale. Per 1-mmol/L lower LDL-C, the estimated reduction in primary MACE was HR=0.76 (95% CI: 0.66, 0.88) for time-updated LDL-C, and HR=0.75 (95% CI: 0.64, 0.88) for time-updated average LDL-C, in the unadjusted models. For confirmed MACE, the estimates were HR=0.70 (95% CI: 0.60, 0.82) and HR=0.67 (95% CI: 0.56, 0.79), respectively. CI denotes confidence interval, HR hazard ratio, MACE major adverse cardiovascular event, n number of participants with MACE.
非 KM Figure
Figure 3:Cumulative Probability of MACE with Adjustment for LDL-C as a Mediator using the Vansteelandt Method Cumulative probability of event adjusted for LDL-C (over time) as a mediator, and for natal sex, screening CD4 count and baseline LDL-C, was estimated using the Vansteelandt method. Follow-up time on the x axis is truncated after 5 years to reflect most participants' potential follow-up time given the staggered enrollment, and the percentage of pitavastatin effect on MACE mediated through LDL-C estimated at 5 years of follow-up is shown. CIs were estimated using bootstrap resampling method.
非 KM Figure